CliffBio
small molecule

FLUTICASONE PROPIONATE

FLUTICASONE PROPIONATE

Loss of exclusivitySeptember 2026FDA regulatory exclusivity expiry
CompanyGLENMARK SPECIALTY SA

Drug detail

Brand nameFLUTICASONE PROPIONATE
Active ingredientFLUTICASONE PROPIONATE
Strength0.044MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTSeptember 2026

More from GLENMARK SPECIALTY SA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

FLUTICASONE PROPIONATE patent cliff — loss of exclusivity September 2026 | CliffBio